Literature DB >> 6183739

Characteristics of the amyloid A fibril-degrading activity of human serum.

A M Teppo, C P Maury, O Wegelius.   

Abstract

Radial diffusion in agarose gel containing amyloid A (AA) fibrils was used to study the serum enzyme capable of degrading AA fibrils in vitro. This degradative activity was unaffected by soya bean trypsin inhibitor, tosyl-lysine chloromethyl ketone, and gold thiomalate but was inhibited by bovine pancreatic trypsin inhibitor, phenylmethylsulphonylfluoride, diisopropyl fluorophosphate, alpha 1-antitrypsin, and alpha 2-macroglobulin, indicating that the enzyme involved is a serine protease. Agarose gel electrophoresis showed the enzyme to be an acidic protein with the same electrophoretic mobility as albumin. The molecular weight, measured by gel filtration, was approximately 50,000. The optimum pH of this enzyme was 7.3, and it was fairly heat-resistant. The results suggest that the AA-fibril-degrading activity in human serum is due neither to elastase nor to cathepsin G. It has many characteristics in common with the enzymes unlike elastase that are involved in the complete degradation of serum AA protein.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6183739     DOI: 10.1111/j.1365-3083.1982.tb00728.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  3 in total

Review 1.  Reactive (secondary) amyloidosis and its pathogenesis.

Authors:  C P Maury
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

2.  'Amyloid degrading activity' of human serum, an in vitro clearing effect which does not involve degradation of amyloid fibrils.

Authors:  D Caspi; M L Baltz; A Feinstein; E A Munn; M B Pepys
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

3.  The failure of ascorbic acid therapy to alter the induction or remission of murine amyloidosis.

Authors:  M L Baltz; D Caspi; B E Glatthaar; U Moser; M B Pepys
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.